Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF

Abstract The current study evaluated the effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF. 60 patients were randomized (1:1) to receive dapagliflozin 10 mg once daily, or placebo double blind for 1 year. Patients underwent transthor...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Qianyu Fu, Longhua Zhou, Yuqin Fan, Fenfen Liu, Yuanyuan Fan, Xin Zhang, Li Wang, Lan Cheng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-11-01
Edice:	BMC Cardiovascular Disorders
Témata:	Dapagliflozin Type 2 Diabetes Heart Failure with reduced ejection fraction Left ventricular remodeling Echocardiography
On-line přístup:	https://doi.org/10.1186/s12872-023-03591-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!